ACP
WHWK

Acuta Capital Partners’s Whitehawk Therapeutics WHWK Stock Holding History

Acuta Capital Partners’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8M Hold
3,410,402
– – 8.3% 3
2025
Q4 		$8.25M Hold
3,410,402
– – 5.6% 5
2025
Q3 		$6.48M Hold
3,410,402
– – 6.7% 4
2025
Q2 		$6.38M Hold
3,410,402
– – 8.9% 3
2025
Q1 		$6.07M Buy
3,410,402
+1,561,000
+84% +$4.08M 7.04% 4
2024
Q4 		$5.83M Hold
1,849,402
– – 5.87% 6
2024
Q3 		$3.81M Hold
1,849,402
– – 3.09% 13
2024
Q2 		$2.7M Hold
1,849,402
– – 2.27% 17
2024
Q1 		$4.33M Hold
1,849,402
– – 2.81% 15
2023
Q4 		$3.74M Hold
1,849,402
– – 2.1% 20
2023
Q3 		$8.95M Hold
1,849,402
– – 6% 3
2023
Q2 		$12.6M Hold
1,849,402
– – 8.57% 2
2023
Q1 		$13.4M Hold
1,849,402
– – 9.86% 2
2022
Q4 		$19.6M Hold
1,849,402
– – 12.08% 1
2022
Q3 		$26.1M Buy
1,849,402
+320,000
+21% +$4.21M 11.25% 2
2022
Q2 		$18.8M Hold
1,529,402
– – 10.5% 2
2022
Q1 		$26M Hold
1,529,402
– – 12.13% 2
2021
Q4 		$36.9M Hold
1,529,402
– – 15.53% 1
2021
Q3 		$44.9M Buy
+1,529,402
New +$46.6M 15.85% 1

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Acuta Capital Partners's WHWK Position: Q1 2026 in Review

Acuta Capital Partners held its Whitehawk Therapeutics (WHWK) position steady in Q1 2026 at 3,410,402 shares worth $11.8M. The position accounts for 8.3% of the portfolio, ranked #3.

Acuta Capital Partners first reported a position in WHWK in Q3 2021 and has held it in 19 quarters since. The position peaked at $44.9M in Q3 2021. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Acuta Capital Partners held 3,410,402 shares of Whitehawk Therapeutics worth $11.8M as of Q1 2026.
  • Acuta Capital Partners left its Whitehawk Therapeutics share count unchanged in Q1 2026.
  • Whitehawk Therapeutics made up 8.3% of Acuta Capital Partners's portfolio in Q1 2026, its #3 holding.
  • Acuta Capital Partners first reported a position in Whitehawk Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Acuta Capital Partners's Whitehawk Therapeutics position peaked at $44.9M in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.